Poolbeg Pharma make significant progress in advancing pipeline

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2023.

Interim Results Highlights and Business Update

·    Strong cash balance of £14.1 million as at 30 June 2023 (31 December 2022: £16.2m)

·    Positive results from the POLB 001 LPS human challenge trial. The asset has the potential to be an effective treatment for severe influenza and potentially other acute inflammatory conditions

·    Strategic expansion of POLB 001 into oncology, including as a potential treatment option for Cytokine Release Syndrome (CRS), a side-effect associated with up to 95% of CAR T cell therapies

·    Further to discussions with prospective partners interested in this area, the Company is actively exploring a potential new indication for POLB 001 in oncology beyond CAR T  

·    The Company’s artificial intelligence (AI) programme with CytoReason provided unparalleled insights into influenza infection and successfully identified a number of novel and valuable drug targets

·    The lab-based validation of the Respiratory Syncytial Virus (RSV) drug targets and treatments identified from the Company’s AI-led programme is progressing and expected to complete in H2 2023

·    The Poolbeg-led Oral Vaccine consortium (EncOVac), which was awarded €2.3 million in grant funding, progressed to the next phase of development, marked by the commencement of the encapsulation validation process

·    Continued progress on the Oral GLP-1 agonist proof-of-technology clinical trial preparation. As a result of adopting recommendations from a number of Key Opinion Leaders (KOLs), the clinical trial design has been refined and the trial is expected to commence in H1 2024

·    Industry veteran, Professor Brendan Buckley, appointed as Non-Executive Director in May 2023

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented: “During H1 2023, we made significant progress in advancing our pipeline, bolstered by the strong clinical trial data for POLB 001 and breakthroughs in our AI-led drug discovery programmes, we are building towards becoming an efficient one-stop-shop for biopharma seeking products to in-license. With a cost-effective R&D approach, complemented by a strong balance sheet and multiple non-dilutive funding opportunities, we are well positioned for ongoing development and future growth with a strong focus on our business development activities.”

Change of Name of Nominated Adviser and Joint Broker

The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Cavendish Capital Markets Ltd following completion of its own corporate merger.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Share on twitter
Share on linkedin
Poolbeg Pharma

More articles like this

Poolbeg Pharma

The growing role of AI in drug discovery

Bringing a new drug to market is an enormously complex and expensive process, often taking over a decade and costing upwards of $2 billion. The pharmaceutical industry faces increasing pressure to improve R&D productivity and efficiency. Artificial intelligence

Poolbeg Pharma

Poolbeg Pharma gets go-ahead for Japanese patent

Dublin-based infectious disease specialist Poolbeg Pharma has received a green light from Japan’s patent office, relating to a patent application for the company’s “potential blockbuster treatment” for severe influenza. The Japanese Patent Office has issued a notice of

Poolbeg Pharma

AI Unleashed: Experts from Poolbeg Pharma & CytoReason

Roundtable discussion featuring Artificial Intelligence hot topics, such as: The future of AI How AI could have contributed to the COVID-19 pandemic Highlights from the exciting collaboration between Poolbeg Pharma and CytoReason. Speakers: Jeremy Skillington – CEO of

Poolbeg Pharma

Poolbeg Pharma plc granted allowance from the Japanese Patent Office

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application. The

Poolbeg Pharma

Poolbeg Pharma patent opposition to be withdrawn

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that the opposition to one of its European patents (Immunomodulator I) that was previously filed by a third party is to be

Poolbeg Pharma

AI to revolutionise drug development by 2026

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development, within the

Poolbeg Pharma

Poolbeg Pharma’s Oral Vaccine Platform

By delivering vaccines to the gut, oral vaccines can trigger ‘mucosal immunity’ which prevents pathogens infecting the body by producing a protective response in the areas of the body where there is a high level of infectious threat,

Poolbeg Pharma

AI Unleashed: Featuring Experts from Poolbeg Pharma & CytoReason

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma

The potential benefits of AI in the development of medicines

Warnings about the potential threats of artificial intelligence (AI) technology have been coming from various industries. However, one of Britain’s largest drug firms, GlaxoSmithKline (GSK), believes that the use of cutting-edge AI could have a positive impact on

Poolbeg Pharma

AI will be a game-changer for medicine

Warnings about the potential threats of artificial intelligence (AI) technology have been coming thick and fast from a wide range of industries. But the use of cutting-edge AI could benefit us all by dramatically speeding up the development

Poolbeg Pharma

The role of generative AI in drug discovery

The field of drug discovery is challenging and time-consuming, but generative artificial intelligence (AI) has the potential to revolutionize this process. Generative AI, a subfield of AI, focuses on creating new data instances that resemble existing data. In

Poolbeg Pharma

How is AI transforming drug discovery?

The emergence of AI, notably in the field of drug discovery, is reshaping the future of medicine The emergence of artificial intelligence (AI), notably in the field of drug discovery, is reshaping the future of medicine. The pharmaceutical business is

No more posts to show